78 related articles for article (PubMed ID: 18800614)
21. Investigational drugs targeting FLT3 for leukemia.
Ustun C; DeRemer DL; Jillella AP; Bhalla KN
Expert Opin Investig Drugs; 2009 Oct; 18(10):1445-56. PubMed ID: 19671038
[TBL] [Abstract][Full Text] [Related]
22. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657.
Goemans BF; Zwaan CM; Cloos J; de Lange D; Loonen AH; Reinhardt D; Hählen K; Gibson BE; Creutzig U; Kaspers GJ
Leuk Res; 2010 Oct; 34(10):1302-7. PubMed ID: 20435347
[TBL] [Abstract][Full Text] [Related]
23. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.
Sritana N; Auewarakul CU
Exp Mol Pathol; 2008 Dec; 85(3):227-31. PubMed ID: 18977345
[TBL] [Abstract][Full Text] [Related]
24. A novel point mutation within the juxtamembrane domain of the flt3 gene in acute myeloid leukemia.
Gianfelici V; Diverio D; Breccia M; Buffolino S; Derme V; Di Lascio A; Marinelli M; Santangelo S; Meloni G; Foà R
Ann Hematol; 2011 Jul; 90(7):845-6. PubMed ID: 20924583
[No Abstract] [Full Text] [Related]
25. Effects of the protein tyrosine kinase inhibitor, SU5614, on leukemic and normal stem cells.
Arseni N; Ahmed F; Hiddemann W; Buske C; Feuring-Buske M
Haematologica; 2005 Nov; 90(11):1577-8. PubMed ID: 16266907
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.
Winkler J; Rech D; Kallert S; Rech J; Meidenbauer N; Roesler W; Mackensen A
Leuk Res; 2010 Oct; 34(10):e270-2. PubMed ID: 20627386
[No Abstract] [Full Text] [Related]
27. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
[TBL] [Abstract][Full Text] [Related]
28. Pyrimido-oxazepine as a versatile template for the development of inhibitors of specific kinases.
Pan W; Liu H; Xu YJ; Chen X; Kim KH; Milligan DL; Columbus J; Hadari YR; Kussie P; Wong WC; Labelle M
Bioorg Med Chem Lett; 2005 Dec; 15(24):5474-7. PubMed ID: 16198560
[TBL] [Abstract][Full Text] [Related]
29. [Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].
Spiekermann K; Hiddemann W; Schnittger S
Dtsch Med Wochenschr; 2005 Apr; 130(16):1020-5. PubMed ID: 15830315
[No Abstract] [Full Text] [Related]
30. FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targeting.
Giles FJ
Leuk Res; 2006 Dec; 30(12):1469-70. PubMed ID: 16631251
[TBL] [Abstract][Full Text] [Related]
31. Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.
Lee SH; Paietta E; Racevskis J; Wiernik PH
Am J Hematol; 2009 Oct; 84(10):701-2. PubMed ID: 19714594
[No Abstract] [Full Text] [Related]
32. Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia.
Podesta JE; Sugar R; Squires M; Linardopoulos S; Pearson AD; Moore AS
Leuk Res; 2011 Sep; 35(9):1273-5. PubMed ID: 21665275
[TBL] [Abstract][Full Text] [Related]
33. Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia.
de Vries AC; Stam RW; Schneider P; Niemeyer CM; van Wering ER; Haas OA; Kratz CP; den Boer ML; Pieters R; van den Heuvel-Eibrink MM
Haematologica; 2007 Nov; 92(11):1557-60. PubMed ID: 18024405
[TBL] [Abstract][Full Text] [Related]
34. Preclinical targeting of NF-kappaB and FLT3 pathways in AML cells.
Griessinger E; Frelin C; Cuburu N; Imbert V; Dageville C; Hummelsberger M; Sirvent N; Dreano M; Peyron JF
Leukemia; 2008 Jul; 22(7):1466-9. PubMed ID: 18239622
[No Abstract] [Full Text] [Related]
35. [The present status of, and problems with the development of FLT3 kinase inhibitors].
Kiyoi H
Rinsho Ketsueki; 2006 Apr; 47(4):270-7. PubMed ID: 16715961
[No Abstract] [Full Text] [Related]
36. ENMD-2076 for hematological malignancies.
How J; Yee K
Expert Opin Investig Drugs; 2012 May; 21(5):717-32. PubMed ID: 22397360
[TBL] [Abstract][Full Text] [Related]
37. The use of salt-inducible kinase inhibitors to treat autoimmune and inflammatory diseases: evaluation of WO2013136070.
Norman P
Expert Opin Ther Pat; 2014 Aug; 24(8):943-6. PubMed ID: 24745372
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenomics suggests new treatment approach for leukaemia.
Senior K
Drug Discov Today; 2002 Aug; 7(15):791-2. PubMed ID: 12546960
[No Abstract] [Full Text] [Related]
39. FLT3 antibody-based therapeutics for leukemia therapy.
Li Y; Zhu Z
Int J Hematol; 2005 Aug; 82(2):108-14. PubMed ID: 16146840
[TBL] [Abstract][Full Text] [Related]
40. [Novel molecularly target therapies for leukemia].
Kiyoi H
Nihon Rinsho; 2007 Jan; 65 Suppl 1():611-6. PubMed ID: 17474469
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
